Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Slides:

Advertisements

Similar presentations

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer Rodryg Ramlau, MD,

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers Christos.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France Nicolas.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient Vincent Fallet, MD, Anne-Marie.

Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell.

Presentation transcript:

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2) Jacques Cadranel, MD, PhD, Audrey Mauguen, MSc, Michele Faller, MD, PhD, Gérard Zalcman, MD, PhD, Marie-Pierre Buisine, PharmD, PhD, Virginie Westeel, MD, PhD, Elisabeth Longchampt, MD, Marie Wislez, MD, PhD, Bruno Coudert, MD, Catherine Daniel, MD, Bruno Chetaille, MD, Stephane Michiels, PhD, Helene Blons, MD, PhD, Jerome Solassol, MD, Florence De Fraipont, PharmD, PhD, Pascal Foucher, MD, Thierry Urban, MD, PhD, Ludovic Lacroix, MD, PhD, Virginie Poulot, LabTec, Elisabeth Quoix, MD, PhD, Martine Antoine, MD, Guillaume Danton, LabTec, Franck Morin, Ms, BSc, Christos Chouaid, MD, PhD, Jean-Pierre Pignon, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 10, Pages 1490-1502 (October 2012) DOI: 10.1097/JTO.0b013e318265b2b5 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Flow chart. EGFR-TKI, epidermal growth factor tyrosine kinase inhibitor. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Progression-free survival and overall survival curves for A, the clinical population (n = 522), and (B) biological population (n = 307). m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 A, Progression-free survival and (B) overall survival curves by mutation status. m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 A, Regression tree for PFS and (B) PFS curves corresponding to the four final groups of the regression tree. PFS, progression-free survival; PS, performance status; HR, hazards ratio; m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 A, Regression tree for OS and (B) OS curves corresponding to the five final groups of the regression tree. PS, performance status; HR, hazards ratio; OS, overall survival; m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions